Company | Humana Inc. | Ticker | HUM |
Earnings Date | July 29, 2026 (8:00 AM ET) | Reporting Period | Q2 2026 (June 30, 2026) |
Prepared | July 28, 2026 | Sector ETF Benchmark | XLV (Health Care Select Sector SPDR) |
Key Takeaway: The setup into Q2 2026 is cautiously constructive — consensus sits at a manageable bar (~$7.01 adj. EPS) and the biggest swing factor is whether the Insurance benefit ratio prints at or below the guided "slightly above 91%" level, with any favorability likely to drive upside to full-year guidance confidence.
Bar: Consensus adj. EPS of ~$7.01 for Q2 2026 (Visible Alpha) implies roughly 80–85% of the full-year "at least $9.00" guide, squarely in line with management's own Q2 cadence guidance — making this a bar that is achievable but not easy. The Insurance segment benefit ratio is the critical KPI: management guided "slightly above 91%" vs. the Q1 actual of 89.4%, and consensus sits at ~91.3%, leaving limited room for upside surprise on the ratio itself but meaningful downside if utilization re-accelerates. Guidance/Tone: Management's posture on the Q1 call was deliberately measured — they built IBNR reserves 35% above membership growth, explicitly said they wanted to "see what happens at the end of Q2" before feeling better, and flagged that April trends were "fairly consistent" with Q1. That conservatism is a feature, not a bug: it sets a low bar for reserve releases in Q2 and H2. Estimate Trajectory: Q2 adj. EPS estimates rose sharply from ~$4.32 in February 2026 to ~$6.47 post-Q1 print and have continued drifting higher to ~$7.01 today — a ~62% upward revision since the February trough — tracking management's guidance affirmation and improving utilization data. The FY2026 consensus of ~$8.93 sits just above the "at least $9.00" floor, suggesting the Street is not yet pricing in meaningful upside. Stock Setup: HUM has rallied ~60% from its April 29 earnings-day close of ~$243 to ~$389 today, driven almost entirely by multiple re-rating (EV/EBITDA expanded from ~11x to ~16x over 3 months) rather than earnings revisions — meaning the stock has priced in significant execution confidence. At ~29x NTM P/E, the valuation is no longer cheap, and any benefit ratio miss or guidance cut would be punished. Wildcard: The single biggest swing factor is the BY'28 Stars update — management promised to share progress "once the hybrid season is complete" on the Q2 call. A positive Stars signal could re-rate the stock further; any disappointment or ambiguity on the October Stars outlook would likely reverse a portion of the recent rally.
Key Takeaway: Consensus sets a manageable bar on EPS (~$7.01) and the benefit ratio (~91.3%), but the stock's sharp re-rating means any miss on the Insurance benefit ratio — the single most-watched KPI — carries outsized downside risk. Total MA membership is the secondary swing factor, with consensus expecting modest sequential growth to ~7.19M.
KPI | Q1 2026 Actual | Q2 2025 Actual (Prior Year) | Q2 2026 Consensus Estimate | YoY Change | Guidance | Consensus vs. Guidance |
Adj. EPS (Diluted Operating) | $10.31 | $6.27 | $7.01 | +11.8% YoY | ~80–85% of FY "at least $9.00" = ~$7.20–$7.65 midpoint | ~−3% to −8% below guidance midpoint |
Total Revenues | $39.6B | $32.4B | $40.6B | +25.4% YoY | No specific Q2 revenue guidance | N/A |
Insurance Benefit Ratio – Operating (%) | 89.4% | 89.9% | 91.3% | +140 bps YoY | "Slightly above 91%" | +30 bps above guidance midpoint |
Total MA Membership | 7.12M | 5.80M | 7.19M | +24.0% YoY | ~25% FY growth (Individual MA) | Tracking in line |
Individual MA Membership | 6.39M | 5.23M | 6.47M | +23.8% YoY | ~25% FY growth affirmed | Tracking in line |
Sources: Visible Alpha Consensus and Actuals Data (EPS, Total Revenues, Benefit Ratio, MA Membership). Q2 2026 guidance from HUM Q1 2026 Earnings Call transcript and 8-K EX-99.3 (April 29, 2026).
Quarter | KPI | Reported | Consensus | Surprise % | Result |
Q1 2026 | Adj. EPS | $10.31 | $10.16 | +1.5% | Beat |
Q1 2026 | Ins. Benefit Ratio | 89.4% | 89.8% | −40 bps | Beat (lower = better) |
Q4 2025 | Adj. EPS | -$3.96 | -$4.03 | +1.7% | Beat |
Q4 2025 | Ins. Benefit Ratio | 93.1% | 93.4% | −30 bps | Beat (lower = better) |
Q3 2025 | Adj. EPS | $3.24 | $2.97 | +9.1% | Beat |
Q3 2025 | Ins. Benefit Ratio | 91.1% | 91.1% | 0 bps | In Line |
Q2 2025 | Adj. EPS | $6.27 | $5.98 | +4.8% | Beat |
Q2 2025 | Ins. Benefit Ratio | 89.9% | 90.0% | −10 bps | Beat (lower = better) |
Q1 2025 | Adj. EPS | $11.58 | $10.05 | +15.2% | Beat |
Q1 2025 | Ins. Benefit Ratio | 87.4% | 87.6% | −20 bps | Beat (lower = better) |
Q4 2024 | Adj. EPS | -$2.16 | -$2.23 | +3.1% | Beat |
Q4 2024 | Ins. Benefit Ratio | 91.9% | 91.8% | +10 bps | Slight Miss |
Q3 2024 | Adj. EPS | $4.16 | $3.39 | +22.7% | Beat |
Q3 2024 | Ins. Benefit Ratio | 90.5% | 90.5% | 0 bps | In Line |
Pattern: HUM has beaten adj. EPS consensus in 7 of the last 8 quarters, with the benefit ratio also printing at or below consensus in 6 of 8 quarters — a consistent pattern of conservative guidance and modest upside delivery. The one benefit ratio miss (Q4 2024) coincided with the Stars-driven earnings trough. Source: Visible Alpha Consensus and Actuals Data.
Key Takeaway: Full-year adj. EPS guidance of "at least $9.00" was affirmed at Q1 earnings with no post-earnings revision; the only change since April 29 was a modest GAAP EPS cut (to "at least $8.36" from "at least $8.89") due to non-operating items. Management tone is measured-to-constructive — they want to see Q2 close before upgrading confidence, but all early indicators are tracking in line to better.
Metric | Initial Guidance (Q1 2026 Earnings, Apr 29) | Revised Guidance | Current Consensus | Note |
FY 2026 Adj. EPS | At least $9.00 | — | $8.93 | Affirmed; no post-earnings change. Consensus sits just below the floor, implying Street not yet pricing upside. |
FY 2026 GAAP EPS | At least $8.89 | Revised to at least $8.36 | N/A (GAAP) | ↓ Lowered at Q1 print (Apr 29); non-operating items only; no change to adj. EPS guidance. |
Q2 2026 Adj. EPS Cadence | ~80–85% of FY adj. EPS | — | $7.01 | Consensus at ~78% of FY guide midpoint — slightly below the guided cadence range. |
Q2 2026 Insurance Benefit Ratio | "Slightly above 91%" | — | 91.3% | Consensus in line with guidance; no cushion for upside surprise on ratio. |
FY 2026 Insurance Benefit Ratio | 92.75% ±25 bps | — | 92.75% | Affirmed; consensus exactly at midpoint. |
FY 2026 Consolidated OCR | 10.0% ±25 bps | — | N/A — not separately tracked in VA | Affirmed; Q1 actual was 10.0% (adj.), 50 bps improvement YoY. |
FY 2026 Individual MA Membership Growth | ~25% over 2025 | — | Tracking in line (Q1 +22% YTD) | Affirmed; Q1 YTD growth of ~1.14M (+22%) tracking toward full-year target. |
Stars BY'28 Outlook | "Top quartile" recovery; unchanged | — | N/A | Q2 call will include hybrid season update — key catalyst. Management 5% ahead of prior year HEDIS gap closure pace. |
Sources: HUM Q1 2026 Earnings Release (8-K EX-99.1, Apr 29, 2026); HUM Q1 2026 Earnings Call Transcript (Apr 29, 2026); HUM 8-K EX-99.3 Prepared Remarks (Apr 29, 2026); Visible Alpha Consensus and Actuals Data.
Key Takeaway: Q2 2026 adj. EPS estimates surged ~62% from the February trough to today, driven by the Q1 beat and guidance affirmation — but the current consensus of $7.01 still sits slightly below the implied guidance midpoint (~$7.20–$7.65), suggesting the Street is not fully pricing in the guided cadence. FY2026 estimates have similarly recovered but remain just below the "at least $9.00" floor, leaving room for upward revision if Q2 prints clean.
KPI (Period) | Estimate ~5 Days Post Q1 Earnings (May 6, 2026) | Current Consensus (Jul 28, 2026) | Estimate Δ (%) | Initial Guidance (Q1 Call) | Current Guidance | Guidance Δ | Consensus vs. Guidance (%) |
Adj. EPS — Q2 2026 | $6.89 | $7.01 | +1.7% | ~80–85% of FY ($7.20–$7.65) | Unchanged | — | ~−3% to −8% below midpoint |
Adj. EPS — FY 2026 | $8.75 | $8.93 | +2.1% | At least $9.00 | Unchanged | — | −0.8% below floor |
Adj. EPS — FY 2027 | $15.77 | $16.55 | +5.0% | No formal guidance | No formal guidance | — | N/A |
Ins. Benefit Ratio — Q2 2026 | 91.3% | 91.3% | 0 bps | "Slightly above 91%" | Unchanged | — | +30 bps above guidance |
Ins. Benefit Ratio — FY 2026 | 92.77% | 92.75% | −2 bps | 92.75% ±25 bps | Unchanged | — | At midpoint |
Total MA Membership — Q2 2026 | 7.19M | 7.19M | 0% | ~25% FY growth (Individual MA) | Unchanged | — | Tracking in line |
Commentary: The estimate revision story since Q1 earnings is one of stabilization rather than acceleration — Q2 and FY2026 EPS estimates are up only ~2% since the post-Q1 baseline, suggesting the Street is waiting for Q2 confirmation before moving numbers higher. The most notable revision is FY2027 adj. EPS, up ~5% since May 6 to $16.55, reflecting growing confidence in the 2028 earnings recovery thesis. The benefit ratio consensus has been anchored exactly at guidance, leaving no cushion for upside surprise on that metric. Source: Visible Alpha Consensus and Actuals Data.
Key Takeaway: HUM's +60% rally since Q1 earnings (Apr 29) has been driven almost entirely by multiple re-rating (EV/EBITDA expanded from ~11x to ~16x over 3 months), not earnings revisions — the stock has dramatically outperformed both XLV (+17%) and the S&P 500 (+4%) over the same period. This multiple-led rally is durable only if Q2 confirms the utilization and margin trajectory; a benefit ratio miss would expose the stock to meaningful multiple compression.
The chart below shows HUM, XLV (Health Care Select Sector SPDR ETF), and SPY (S&P 500 ETF) indexed to 100 at the Q1 2026 earnings date (April 29, 2026). Key events are marked with vertical lines.
[Image not found: gs://lum-production-user-data/conversations/conv_01k7aqhqhkfhfbhqhqhqhqhqhq/plotly_charts/hum_stock_performance.json]
HUM vs. XLV vs. SPY — Indexed to 100 at Q1 2026 Earnings (Apr 29, 2026). Note: Chart generated from Yahoo Finance price data. HUM: dark navy; XLV: mid-grey dashed; SPY: light grey dashed.
Metric | HUM | XLV | SPY |
Price at Q1 Earnings (Apr 29, 2026) | $243.12 | $142.84 | $711.58 |
Price as of Jul 28, 2026 | $388.71 | $167.26 | $740.86 |
Return Since Q1 Earnings | +59.9% | +17.1% | +4.1% |
NTM EV/EBITDA (Current) | ~15.9x | N/A | N/A |
NTM P/E (Current) | ~28.7x | N/A | N/A |
Key Events Since Q1 Earnings:
Source: Stock Price Data (Yahoo Finance). Performance decomposition: internal stock performance decomposition tool.
Key Takeaway: Peers reporting Q2 2026 results (UNH Jul 16, ELV Jul 15, MOH Jul 22, CNC Jul 28) collectively signal that Medicare Advantage medical cost trends are running below initial expectations — a clear positive read-through for HUM's benefit ratio. Medicaid is more mixed (membership attrition, acuity shifts), but HUM's Medicaid exposure is small. The Stars program remains an industry-wide headwind. All commentary below is from Q2 2026 earnings calls/releases (current reporting quarter) only; no prior-quarter stale commentary is included.
Overall Read-Through for HUM: Positive on Medicare Advantage; Negative on Stars industry difficulty; Mixed on commercial (not directly relevant to HUM).
Theme | UNH Commentary (Q2 2026) | Read-Through for HUM | Signal |
MA Medical Cost Trend | "Medical cost trends in Medicare are still running well above historical levels, but below our expectations so far in 2026." UNH now expects 2026 Medicare trend to come in below its initial ~10% estimate. | Directly positive for HUM's Q2 benefit ratio. If the largest MA insurer is seeing below-expectation Medicare trend, HUM's guided "slightly above 91%" benefit ratio may prove conservative. | Positive |
MA Margins | "We now expect Medicare margins to finish 2026 above 3%." Membership retention better than anticipated. | Validates HUM's path to margin recovery. HUM targets doubling individual MA margin in 2026 (adj. for Stars); UNH achieving >3% is a positive sector signal. | Positive |
2027 Trend Outlook | "Not expecting a meaningful deviation from the still elevated underlying core trends" for 2027 bids. Benefit adjustments and selective market exits planned. | Confirms HUM's own messaging that the funding-vs.-trend gap persists into 2027, necessitating benefit cuts. No surprise here; consistent with HUM's explicit 2027 bid strategy. | Neutral |
Stars Program | "The Stars program has continued to get more challenging in recent years, as evidenced by 2026 industry scores at the lowest level in about a decade." | Industry-wide headwind confirms HUM is not alone in facing Stars pressure. However, HUM's specific BY'28 recovery thesis depends on its own operational execution, not industry averages. | Mixed |
MA Enrollment | UNH now expects full-year MA enrollment to decline by ~1.1M. Retention better than anticipated but still a net decline. | Contrast with HUM: HUM is growing MA membership ~25% YoY. UNH's decline reflects its own repositioning; HUM's growth is a differentiated positive. | Positive |
Care Management / AI | Optum Health value-based care margins "slightly better than expected"; ~10% reduction in inpatient admissions in some regions. AI-based prior auth achieving 96% first-pass approval. | Positive for integrated care model thesis. HUM's CenterWell primary care strategy mirrors this approach; effective care management is a margin lever. | Positive |
Overall Read-Through for HUM: Positive on MA performance and margins; Mixed on Medicaid; Positive on Stars investment discipline.
Theme | ELV Commentary (Q2 2026) | Read-Through for HUM | Signal |
MA Performance | "Results were stronger than expected and were a contributor to our outperformance in the quarter." Deliberate portfolio repositioning "translating into stronger performance." On track for at least 2% MA operating margin in 2026. | Strong positive read-through. ELV's MA outperformance driven by disciplined plan design and favorable claims experience — same levers HUM is pulling. Validates the sector-wide MA improvement narrative. | Positive |
MA Utilization | "Seeing moderately lower surgery trends" in Medicare. "Favorable claims experience." However, "underlying medical cost trend is still outpacing program funding." | Lower surgical trends are a direct positive for HUM's Q2 benefit ratio. The caveat that trend still outpaces funding is consistent with HUM's own 2027 bid messaging. | Positive |
2027 Bid Discipline | "Submitted bids with a prudent view of trend and a continued focus on sustainable margin improvement." Emphasis on dual-eligible members and appropriate returns. | Consistent with HUM's explicit margin-first, retention-second, growth-third 2027 bid hierarchy. Industry-wide pricing discipline reduces competitive risk for HUM. | Positive |
Stars Investment | Stars is a "core enterprise priority" and "multi-year journey." Significant investments in AI-powered member engagement, omnichannel outreach, and clinical data interoperability. | Validates HUM's Stars recovery investment thesis. Both companies are investing heavily in the same levers; HUM's BY'28 target is achievable if execution matches ELV's approach. | Positive |
Medicaid | Full-year Medicaid operating margin outlook of approximately -1.75% unchanged. Cost drivers "elevated and concentrated" in behavioral health, specialty pharmacy, outpatient surgery, and ED utilization. July rate activity "constructive" and modestly favorable. | Mixed for HUM's small Medicaid segment. Elevated cost drivers are a headwind, but improving rate environment is a partial offset. HUM's Medicaid exposure is limited (~50K member growth in 2026). | Mixed |
Raised FY2026 Guidance | ELV raised FY2026 adj. EPS guidance to "at least $27" (from prior guidance), citing Q2 outperformance. Confident in returning to at least 12% adj. EPS growth in 2027. | Positive sector signal. ELV's guidance raise increases probability that HUM can also affirm or raise its "at least $9.00" FY2026 adj. EPS floor on tomorrow's call. | Positive |
Overall Read-Through for HUM: Positive on Medicare duals (lower-than-expected trend); Mixed on Medicaid (stable but rate-trend imbalance persists); Negative on ACA Marketplace (not directly relevant to HUM).
Theme | MOH Commentary (Q2 2026) | Read-Through for HUM | Signal |
Medicare Duals Trend | Q2 Medicare MCR of 90.7%, "very favorable to expectations" driven by duals outperformance. Full-year Medicare MCR guidance improved 180 bps. Medical cost trend in duals now forecast at 4% vs. initial 6% assumption. "Trend is lower in just about all categories in duals — inpatient and pharmacy down meaningfully." | Strong positive read-through for HUM's dual-eligible and Medicare populations. Lower inpatient and pharmacy trends in duals directly support HUM's benefit ratio guidance. HUM has significant dual-eligible exposure through its Medicaid SNP programs. | Positive |
Medicaid Medical Cost Trend | Medicaid MCR of 92.7% in Q2, in line with expectations. Full-year medical cost trend unchanged at 5%. "The imbalance between rates and trend appears to have stabilized." High trend categories (behavioral health, professional visits, inpatient) expected to remain stable in H2. | Neutral-to-slightly positive for HUM's Medicaid segment. Stable trend at 5% is manageable; rate-trend imbalance stabilizing is a positive signal for future margin recovery. | Mixed |
Medicaid Work Requirements (OB3) | Expects membership reductions of 2–3% per year for three years with only a minor acuity shift. "Nothing we learned in Nebraska causes us to change from our long-term assumption." | Manageable for HUM's Medicaid segment. Gradual, minor acuity shift is better than feared; HUM's Medicaid exposure is primarily in SNP/dual programs which may be less affected. | Positive |
Stars Court Rulings | "We do not expect the recent Stars court rulings to have a material impact on our business or product offerings." | Neutral for HUM. MOH's Stars exposure is different from HUM's. HUM's Stars litigation (2025 ratings challenge) was already rejected; the focus is now on BY'28 operational recovery. | Neutral |
2027 Outlook | 2027 premium outlook ~$46.5B (+11% YoY). EPS building blocks sum to more than $10/share. Optimistic about Medicaid margin improvement in 2027 as rate-trend imbalance corrects. | Positive sector signal for 2027 managed care recovery. Validates HUM's own 2028 earnings recovery thesis — if Medicaid margins recover in 2027, the broader managed care environment is improving. | Positive |
Overall Read-Through for HUM: Positive on Medicare MA utilization and PDP; Mixed on Medicaid (membership attrition, acuity); Mixed on Stars (industry headwinds from methodology changes).
Theme | CNC Commentary (Q2 2026) | Read-Through for HUM | Signal |
MA Medical Costs | "Medicare segment once again delivered outperformance in Q2." "Medical costs remain elevated when compared to historical averages, but year-to-date trend is running modestly favorable to expectations." "Key medical cost drivers were stable quarter over quarter." | Positive read-through for HUM's Q2 benefit ratio. Stable and modestly favorable MA cost trends across multiple peers is a strong signal that HUM's guided "slightly above 91%" benefit ratio is achievable or beatable. | Positive |
PDP Performance | PDP to deliver pre-tax margin greater than 3% in 2026 vs. 2% guided at start of year. "Elevated specialty drug trend remains lower than original expectations through H1." | Positive for HUM's CenterWell Pharmacy and standalone PDP business. Lower-than-expected specialty drug trend is a direct benefit to HUM's pharmacy cost line. | Positive |
Stars Methodology Headwinds | "Along with the industry, facing headwinds from artificial cut point increases and overall Stars program methodology changes, not to mention uncertainty around the future of the program overall." | Negative industry-wide signal. CMS methodology changes create uncertainty for HUM's BY'28 Stars recovery thesis. Even strong operational execution may be challenged by external cut point changes. | Negative |
Medicaid Membership Attrition | Ended Q2 with just over 12M members, "a slightly larger step down in membership than anticipated." Now expects full-year Medicaid membership down 8–9% vs. prior view of down 6%. Slight uptick in acuity from expansion population. | Negative for Medicaid managed care broadly. HUM's Medicaid segment is small and focused on SNP/dual programs, which may be less affected than CNC's broad Medicaid book. Monitor HUM's Medicaid membership guidance. | Negative |
Medicaid Rates | Full-year 2026 composite rate forecast improved from ~4.5% to ~5%. "71 rates coming in better than expected." | Positive for Medicaid rate environment. Better-than-expected rate development partially offsets the membership attrition headwind for HUM's Medicaid segment. | Positive |
Risk Adjustment / Quality Settlements | Medicare segment benefited from ~$160M in favorable PDP 2025 risk adjustment and quality settlements in Q2 — a non-recurring item. | Positive for Q2 2026 specifically. If HUM also received favorable 2025 risk adjustment settlements, this could provide a one-time Q2 boost. Non-recurring, so not a 2027 tailwind. | Positive |
Theme | UNH | ELV | MOH | CNC | Net Signal for HUM |
MA Medical Cost Trend | ✅ Below expectations | ✅ Lower surgery trends | ✅ Duals trend at 4% vs. 6% est. | ✅ Modestly favorable to expectations | Positive |
MA Margins | ✅ >3% expected for 2026 | ✅ ≥2% on track | ✅ Duals outperforming | ✅ MA outperformance | Positive |
Stars Program | ⚠️ Industry at decade low | ✅ Investing heavily | — Not material | ❌ Cut point headwinds | Mixed |
Medicaid Trend | — Not primary | ⚠️ Elevated, stable | ✅ Stable at 5% | ❌ Membership attrition | Mixed |
PDP / Pharmacy Trend | — | — | — | ✅ Specialty drug below expectations; >3% margin | Positive |
2027 Bid Discipline | ✅ Disciplined; benefit adjustments | ✅ Prudent trend view | ✅ Optimistic on 2027 recovery | ✅ Break-even or better in 2027 | Positive |
Sources: UNH Q2 2026 Earnings Call Transcript (Jul 16, 2026); ELV Q2 2026 Earnings Call Transcript (Jul 15, 2026); MOH Q2 2026 Earnings Call Transcript (Jul 22, 2026); CNC Q2 2026 Earnings Call Transcript (Jul 28, 2026). All commentary is from Q2 2026 earnings events only; no prior-quarter stale commentary included.
Key Takeaway: The most important development since Q1 earnings is the CY2027 Final MA Rate Notice (April 2026) — better than the preliminary near-flat proposal at ~+2.5%, but still below elevated medical cost trend, confirming HUM's explicit plan to cut benefits in 2027 bids. The leadership transition in the Insurance segment (Renaudin retiring June 29) is a secondary watch item heading into the Q2 call.
Key Takeaway: No open-market insider purchases or sales (Form 4 codes P/S) were identified for HUM in the period since Q1 2026 earnings (April 29, 2026 through July 28, 2026) based on SEC Form 4 filings data. The absence of insider selling during a ~60% stock rally is a mild positive signal — insiders are not rushing to monetize the recovery. No 10b5-1 plan initiations were flagged in the data pull.
Name | Title | Transaction Type | Value | Date | Note |
N/A | N/A | N/A | N/A | N/A | No open-market buys or sells (Form 4 codes P/S) identified in the Apr 29 – Jul 28, 2026 window. Source: SEC Form 4 Filings Database. |
Note: The SEC Form 4 database was queried for open-market purchases (code P) and sales (code S) for HUM between April 29, 2026 and July 28, 2026. No transactions matching these criteria were returned. Routine equity award grants (code A) and option exercises (code M) are excluded per standard methodology. The absence of discretionary insider selling during a significant stock rally is consistent with management's expressed confidence in the 2028 earnings recovery thesis.